Mammalian target of rapamycin;novel insight for management of inflammatory bowel diseases

作     者：Naser-Aldin Lashgari Nazanin Momeni Roudsari Saeideh Momtaz Amir Hossein Abdolghaffari 

作者机构：Department of Toxicology and PharmacologyFaculty of PharmacyTehran Medical SciencesIslamic Azad UniversityTehran ***Iran Department of PharmacologyMedicinal Plants Research CenterInstitute of Medicinal PlantsACECRKaraj ***Iran Toxicology and Diseases Group(TDG)Pharmaceutical Sciences Research Center(PSRC)The Institute of Pharmaceutical Sciences(TIPS)Tehran University of Medical SciencesTehran ***Iran Department of Toxicology and PharmacologyFaculty of PharmacyTehran University of Medical SciencesTehran ***Iran Gastrointestinal Pharmacology Interest Group(GPIG)Universal Scientific Education and Research Network(USERN)Tehran ***Iran 

出 版 物：《World Journal of Pharmacology》 (世界药理学杂志)

年 卷 期：2022年第11卷第1期

页      面：1-5页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Inflammatory bowel diseases Inflammation Mammalian target of rapamycin Mammalian target of rapamycin inhibitors 

摘      要：Inflammatory bowel diseases(IBDs),with blurred etiology,show a rising trend and are of global *** various factors involved in IBD pathogenesis and development,inflammation has been shown to play a major *** of the molecular and cellular pathways that induce IBD is an emerging subject to develop targeted *** target of rapamycin(mTOR)is one the most common receptors of many inflammatory pathways,including that of *** this end,we intend to overview the mTOR inhibitors for their possible efficacy in present and future approaches to treatment of IBD.